Intellia Therapeutics said Monday it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.
The company’s stock plummeted more than 35% in morning trading.
Liver damage has been a known risk for many CRISPR-based medicines in development, in part because they often involve trying to knock out or modify a gene in that organ. In 2024, Verve Therapeutics shelved its lead program for heart disease and moved to a backup molecule, in part over liver safety concerns.
Intellia, though, had encountered few serious safety concerns, despite dosing hundreds of patients across its clinical trials — more than any other company attempting to edit genes directly in patients.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
